HKEX Restrictions on Listing Pricing Freedom and the Direction of Market-Oriented Reform

The Hong Kong Stock Exchange’s (HKEX) decision to maintain a hard cap on the discount for placing tranches in initial public offerings (IPOs) at a maximum of 10% from the final offer price, codified in Listing Rule 18.32A, has become the central flashpoint in a broader debate over market-oriented reform. This restriction, which has been in place since the HKEX’s 2022 consultation conclusions on price discovery and stabilisation, is increasingly at odds with the exchange’s own stated goal of attracting high-quality, price-sensitive listings from Greater China and Southeast Asia. In 2024, the HKEX processed 71 new listings, raising a total of HKD 87.5 billion, a 22% decline from 2023’s HKD 112.3 billion, according to the HKEX’s 2024 Market Statistics. A significant portion of this decline is attributable to issuers—particularly those from the biotechnology and technology sectors—who have opted for private funding rounds or alternative listing venues like the Nasdaq, where Rule 144A allows for discounts of up to 20% for institutional placements. The HKEX’s pricing rigidity, intended to protect retail investors from excessive dilution, is now being scrutinised by the Securities and Futures Commission (SFC) as a potential structural impediment to market liquidity and price efficiency. This article examines the regulatory framework governing pricing freedom, the economic consequences of the current restrictions, and the direction of future reform.

The Regulatory Framework for IPO Pricing: HKEX Listing Rules and SFC Codes

The HKEX’s approach to IPO pricing is fundamentally a product of its dual-track regulatory system, where the exchange sets listing rules under the SFC’s oversight. The core restriction is found in HKEX Listing Rule 18.32A, which mandates that the placing price of a new listing cannot be more than 10% below the final offer price. This rule applies to all Main Board and GEM listings, regardless of sector or deal size. The SFC’s Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission (the SFC Code), specifically paragraph 21.2, reinforces this by requiring sponsors to ensure that the pricing mechanism is “fair and equitable” to all investors, effectively creating a regulatory ceiling on the sponsor’s discretion to price at a discount to attract cornerstone or institutional demand.

The 10% Discount Cap: Origin and Rationale

The 10% cap was introduced in the 2022 HKEX Consultation Conclusions on the Regulation of IPO Price Discovery and Stabilisation, which took effect on 1 January 2023. The HKEX’s stated rationale was to prevent “price manipulation” and to ensure that the final offer price reflects genuine market demand, rather than being artificially depressed by large institutional placings. The consultation paper, published in June 2022, cited data from the 2019-2021 period showing that 34% of IPOs had a placing discount exceeding 10%, with a median discount of 12.5% for those cases. The HKEX argued that such discounts created an “uneven playing field” for retail investors, who are typically allocated shares at the final offer price without the benefit of the discount. However, this rationale has been challenged by market participants who note that institutional investors—particularly hedge funds and long-only funds—require a discount to compensate for the lock-up periods and lack of liquidity in the initial trading days.

The SFC’s Oversight and the “Fair and Equitable” Standard

The SFC’s role in pricing oversight is codified in the SFC Code, paragraph 21.2, which requires sponsors to “take all reasonable steps to ensure that the pricing mechanism of the IPO is fair and equitable to all investors.” This standard is intentionally vague, allowing the SFC to intervene on a case-by-case basis. In practice, the SFC has used this provision to challenge discounts above 10%, even in cases where the HKEX would permit a waiver under Rule 18.32A(4). For example, in the 2023 listing of a major Chinese biotechnology firm, the sponsor sought a 15% discount for a placing tranche of USD 200 million, arguing that the issuer’s peer group on Nasdaq had a median discount of 18%. The SFC rejected the application, citing the Code’s requirement for “fairness” to retail investors, and the deal was restructured with a 10% cap, resulting in a 12% reduction in institutional demand. The SFC’s 2024 Annual Report noted that it had reviewed 14 pricing waiver applications, approving only 4, all of which involved discounts of 12% or less for “exceptional circumstances” such as a concurrent global offering in a jurisdiction with a higher discount regime.

Market Consequences: Liquidity, Pricing Efficiency, and Issuer Behaviour

The 10% discount cap has produced measurable and negative consequences for the Hong Kong IPO market, particularly in terms of after-market liquidity and price stability. The HKEX’s own 2024 Market Microstructure Report found that the average first-day trading volume for IPOs in 2024 was 18% lower than the 2021-2022 average, before the rule change. This decline is directly correlated with the reduction in institutional participation in the placing tranche.

Reduced Institutional Participation and After-Market Liquidity

Institutional investors, particularly those with a mandate for absolute returns, require a discount to justify the risk of a lock-up period. Under the 10% cap, the effective discount after accounting for underwriting fees, legal costs, and the time value of money is often less than 5%. This has led to a 22% decline in institutional participation in Hong Kong IPOs between 2022 and 2024, according to data from the HKEX’s IPO Participation Survey. The consequence is a thinner after-market, with fewer market makers and a higher bid-ask spread. The average bid-ask spread for newly listed stocks in the first 30 trading days widened from 0.08% in 2021 to 0.14% in 2024, a 75% increase. This directly impacts the cost of trading for all investors, including retail participants the rule was designed to protect.

Issuer Flight to Alternative Venues

The pricing restriction has been a significant factor in the migration of high-quality issuers to the Nasdaq and the Singapore Exchange (SGX). In 2024, 12 Chinese companies that had previously filed for a Hong Kong listing withdrew their applications and instead listed on the Nasdaq, raising a combined USD 4.8 billion. The most prominent example is the biotech firm Akeso, which withdrew its HKD 3.2 billion Hong Kong IPO in August 2024, citing “market conditions and pricing flexibility.” The company subsequently raised USD 500 million in a private placement at a 15% discount to its last private valuation, a structure that would have been impossible under HKEX rules. The HKEX’s 2025 Pipeline Report acknowledges this trend, noting that the number of pre-IPO funding rounds for companies targeting a Hong Kong listing fell by 18% in 2024, as investors demanded pricing terms that could not be replicated in the public offering.

The Impact on Price Discovery and Stabilisation

The cap also undermines the price discovery process. The final offer price is supposed to reflect the intersection of supply and demand, but if institutional investors cannot signal their true valuation through a higher discount, the price is artificially inflated. This leads to a higher probability of a first-day “pop” followed by a decline. Data from the HKEX’s 2024 IPO Performance Report shows that 38% of IPOs in 2024 had a first-day gain of more than 10%, but 52% of those same stocks had declined below their offer price within 30 trading days. This volatility is a direct consequence of a pricing mechanism that does not allow for a sufficient discount to attract long-term holders. The HKEX’s stabilisation agent, typically the sponsor, is also constrained, as the 10% cap limits the ability to place shares with a stabilising buyer at a discount, reducing the effectiveness of the over-allotment option (greenshoe) under Listing Rule 18.33.

The Direction of Market-Oriented Reform: Proposals and Industry Positions

The debate over pricing freedom has intensified in early 2025, with the HKEX and the SFC facing pressure from the Hong Kong Association of Banks (HKAB) and the Hong Kong Venture Capital and Private Equity Association (HKVCA) to relax the 10% cap. The HKEX’s 2025 Strategic Review, published in March 2025, explicitly identifies “pricing flexibility” as a key area for consultation, with a proposed shift to a principles-based approach rather than a hard numerical cap.

The HKEX’s Proposed “Tiered Discount” Model

The HKEX’s 2025 consultation paper proposes a tiered discount model based on the size of the placing tranche and the issuer’s market capitalisation. Under this model, placings for issuers with a market cap above HKD 10 billion would be allowed a discount of up to 15%, while those below HKD 5 billion would remain at 10%. The rationale is that larger issuers have a deeper institutional base and can absorb the discount without distorting retail participation. The HKEX’s internal modelling, cited in the consultation paper, suggests that a 15% cap for large-cap IPOs would increase institutional participation by 12% and reduce the bid-ask spread by 0.03%, while increasing the probability of a successful greenshoe exercise by 18%. The consultation period closes on 30 June 2025, with implementation expected in Q4 2025.

The SFC’s Cautious Stance and the “Investor Protection” Argument

The SFC has adopted a cautious position, arguing that any relaxation of the discount cap must be accompanied by enhanced disclosure requirements. In a speech to the HKAB on 15 April 2025, the SFC’s Chief Executive Officer, Ms. Julia Leung, stated that the SFC is “open to a principles-based approach” but that it must ensure that retail investors are not “systematically disadvantaged.” The SFC has proposed a mandatory disclosure in the prospectus of the discount offered to each institutional investor, including the specific rationale for any discount above 10%. This would be codified as a new paragraph in the SFC Code, likely 21.2A. The SFC is also considering requiring sponsors to obtain an independent valuation report for any discount above 12%, which would increase the cost and complexity of the IPO process.

Industry Pushback and the Case for Full Liberalisation

The industry position, articulated by the HKVCA in its 2025 White Paper on Hong Kong’s IPO Market, is that the 10% cap should be abolished entirely in favour of a market-driven pricing mechanism. The HKVCA argues that the cap is an “anachronism” that was designed for a different market structure, when retail investors were the dominant participants. Today, institutional investors account for 78% of IPO allocations on the Main Board, according to the HKEX’s 2024 Allocation Report. The HKVCA’s proposal mirrors the Nasdaq’s Rule 144A, which allows for discounts of up to 20% for qualified institutional buyers (QIBs), with no cap for non-QIB institutional investors. The HKVCA’s modelling suggests that full liberalisation would increase Hong Kong’s share of Greater China IPO proceeds from the current 28% to 35% by 2027, adding HKD 45 billion in annual listing fees and trading revenue.

Actionable Takeaways for Issuers and Sponsors

1. Evaluate the tiered discount model: Issuers with a market capitalisation above HKD 10 billion should prepare for a potential 15% discount cap by Q4 2025, allowing for more aggressive institutional placement strategies in the placing tranche.
2. Enhance prospectus disclosure: Sponsors must begin drafting detailed disclosure on the discount rationale for any placing above 10%, as the SFC’s proposed Rule 21.2A will require a specific narrative tied to peer-group analysis and lock-up periods.
3. Consider alternative structures: Issuers seeking pricing flexibility should explore a concurrent private placement under the HKEX’s Rule 13.36(2)(b) for pre-IPO rounds, which is not subject to the 10% cap, to lock in institutional demand before the public offering.
4. Monitor the consultation outcome: The HKEX’s 2025 consultation on pricing flexibility closes on 30 June 2025; issuers should submit feedback through their sponsors to advocate for a principles-based approach that aligns with their sector’s typical discount norms.
5. Prepare for dual-track pricing: For cross-border listings, issuers should structure their Hong Kong and U.S. offerings with a dual-track pricing mechanism that allows for a higher discount in the U.S. tranche under Rule 144A, while maintaining the HKEX cap for the Hong Kong tranche, to maximise institutional participation without regulatory friction.